



Ryvu Therapeutics S.A.  
2 Sternbacha Street, 30-394 Krakow, Poland  
registered in the District Court for the Krakow-Srodmiemie  
in Krakow XI Division of the National Court Register  
KRS number: 0000367359  
VAT ID: PL6792942955



MEDICAL  
RESEARCH  
AGENCY

Krakow, 03<sup>th</sup> December 2024

## REQUEST FOR PROPOSAL No. ABM-03122024A

In connection with the implementation by Ryvu Therapeutics S.A. of the project “The conduct of a phase II, multicentre, open-label clinical trial (RIVER-81) evaluating the safety and efficacy of RVU120 in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia who have failed prior therapy with venetoclax and a hypomethylating agent” no. 2022/ABM/06/00002/P/02 (hereinafter: “Project”) co-financed from the state budget by the Medical Research Agency under the Competition: Development of targeted or personalized medicine based on therapeutic products based on nucleic acids and small-molecule compounds no. ABM/2022/6, Ryvu Therapeutics S.A. invites proposals for the execution of the following defined description of the order.

### I. ORDERING PARTY (hereinafter: “Sponsor”):

Ryvu Therapeutics S.A.  
Sternbacha 2, 30-394 Krakow, Poland  
EU VAT PL6792942955

### II. DESCRIPTION OF THE ORDER:

**This order concerns the execution of organization of transportation and travel expense reimbursement in the phase II clinical study of a study drug in combination with a market drug in patients with AML.**

Due to the need to protect business secrets, the description of the order (subject of the request) will be made available to Bidders who undertake to maintain confidentiality. The Bidder must have a signed confidentiality agreement with the Ordering Party. If the agreement is not in force, an electronically signed CDA must be sent to [vendors.clinical@ryvu.com](mailto:vendors.clinical@ryvu.com). The CDA template is attached as **Appendix 01**. The title of the message must include the RFP reference number i.e. ABM-03122024A.

### III. CONDITIONS FOR PARTICIPATION IN THE PROCEEDINGS:

Bidders that fulfill the following requirements are invited to submit the proposals:

- III.1. Proposal validity period: minimum until 28<sup>th</sup> February 2025.
- III.2. Contract term: deadline for performance of the contract: 30<sup>th</sup> September 2026.  
In the event of prolonging the completion date of the Project stage, the agreement may be extended following changes in the Project co-financing agreement.
- III.3. Payment terms: payment deadline for invoices not less than 30 days.
- III.4. The service can be set up starting from 2<sup>nd</sup> January 2025.
- III.5. Bidder is in a sound economic and financial condition to ensure the performance of the contract.
- III.6. Bidder is not in liquidation or have not been declared bankrupt.

These conditions to be confirmed in **Appendix 02 – Proposal Form**. The assessment of the conditions will be made using the system: meet/does not meet.

### IV. PLACE, DATE, AND PROCEDURE OF SUBMISSION OF PROPOSALS:

- IV.1. The proposal must be submitted by: **13<sup>th</sup> December 2024 at 23.59 CET**.

- IV.2. The proposal must be sent via e-mail to the following address: [vendors.clinical@ryvu.com](mailto:vendors.clinical@ryvu.com). The message with the proposal should refer to the RFP number indicated on the first page: ABM-03122024A.
- IV.3. The proposal and its attachments should be prepared in English.
- IV.4. The proposal must be prepared in accordance with the form constituting Appendix 02 to this RFP and must include the following information: e.g.
- the preferred type and frequency of communication with Sponsor,
  - the method of providing updates or reports to the Sponsor,
  - details on whether the vendor requires advance payments and if so, a clear specification of how these payments will be reconciled.
- IV.5. The Bidder must provide the total price for the total value of the contract consisted with the subject of the request. The proposal must include prices given in EUR or USD.

**V. ADDITIONAL INFORMATION:**

- V.1. The Ordering Party allows for the possibility of placing additional orders (supplementary orders) with the selected Contractor for an amount not exceeding 50% of the value of the contract concluded with the Contractor, provided that such orders are consistent with the subject of the basic contract. The terms and conditions of the agreement may change during the course of the agreement (Ordering Party reserves the right to amend the agreement):
- in relation to the timelines and duration of the agreement – following changes in the scope of the study and Project (e.g. extension of the Project duration, extension of appropriate Project stages, change in research plans);
  - in relation to the number of countries, sites, patients and estimated number of visits. The study is very dynamic in nature, in which the well-being and comfort of patients must be treated as a priority, therefore the estimates specified in Table 1 may change, which, however, will not affect the type/nature of the services.
  - in the event of force majeure as an event which is externally impossible to foresee, and which could not have been prevented and whose consequences and effects could not have been prevented.
  - The Ordering Party reserves the right to make changes to the final order/contract based on the requirements of the study protocol.
- V.2. The Bidders may ask the Ordering Party to clarify the content of this RFP. If the request for clarification of the content of the RFP was received later than by the end of **10th December 2024**, the Ordering Party may provide explanations or leave the application unexamined. Questions must be sent to the following e-mail address: [vendors.clinical@ryvu.com](mailto:vendors.clinical@ryvu.com)
- V.3. Due to the need to protect business secrets, in the event of questions requiring the disclosure of confidential data, the Ordering Party reserves the right to provide explanations after executing the Confidential Disclosure Agreement (CDA). It is allowed to use an electronic signature (including a qualified electronic signature) or a trusted signature (trusted profile).
- V.4. The Ordering Party reserves the right to change the content of the RFP, including changes in the terms of the procedure. Bidders will be informed.
- V.5. The Ordering Party reserves the right to ask the Bidders at any stage of the evaluation of proposals for additional information, documents, additions, or explanations. The Ordering Party's contact with the Bidder will take place by e-mail indicated in the content of the proposal sent by the Bidder.
- V.6. The Ordering Party reserves the right to enter into price negotiations with Bidders who have submitted the proposals and meets the conditions for participating in the proceedings. Arrangements regarding the date of negotiations will be carried out by e-mail. The modified proposal may not contain conditions less favorable than the original proposal.
- V.7. This RFP does not oblige the Ordering Party to conclude a contract.
- V.8. For more information, please contact Magdalena Masiejczyk or Anna Dziejdzicka at the following email address: [vendors.clinical@ryvu.com](mailto:vendors.clinical@ryvu.com)

**ATTACHMENTS:**

Appendix 01 – Mutual Confidentiality Agreement

Appendix 02 – Proposal Form ABM-03122024A

Appendix 03 – Description of the order ABM-03122024A